Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab and Cemiplimab vs Pembrolizumab in Adjuvant High-risk Melanoma
NCT05608291Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 22
01
Overview
A Phase 3 trial of fianlimab in melanoma, sponsored by Regeneron Pharmaceuticals. Started Jan 2023; status: active, not recruiting.
02
Drugs
fianlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05608291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608291.